BS_AGTPCRR4
Posterior Fossa Ependymoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Posterior Fossa Ependymoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Posterior Fossa Ependymoma
- overall_survival_months
- 60.2496714848883
- age_years
- 11.997
- sex
- Male
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG228 | — | — | 0.920 |
| 2 | BS_MBSTWZA6 | pilocytic astrocytoma | — | 0.914 |
| 3 | 62BFF895-C5CC-4F59-8348-2026B659FDF5 | — | — | 0.914 |
| 4 | SRR820209 | GTEX | — | 0.895 |
| 5 | SJEPD031215_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.894 |
| 6 | 3BCD8BE5-753D-43EF-B830-EA4356620A5C | — | — | 0.893 |
| 7 | SRR820133 | GTEX | — | 0.890 |
| 8 | BS_VARR255N | pilocytic astrocytoma | — | 0.886 |
| 9 | BS_T0RKFEKR | pilocytic astrocytoma | — | 0.883 |
| 10 | 31D3488A-212B-4818-8F09-EBF1E8B135AD | — | — | 0.877 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 42 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.528 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.476 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.453 | Inavolisib | — uncovered |
| HYPOXIA | 0.449 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.426 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.383 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.377 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.370 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.357 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.356 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.342 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.337 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.318 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.317 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.314 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.310 | Inavolisib | — uncovered |
| COAGULATION | 0.306 | Binimetinib | — uncovered |
| COMPLEMENT | 0.293 | Inavolisib | — uncovered |
| APOPTOSIS | 0.290 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.290 | Remibrutinib | — uncovered |